NCT04152499 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04152499
Title	Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)
Acronym	MK-2870-001
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Klus Pharma Inc.
Indications	ovarian cancer uterine carcinosarcoma cervical squamous cell carcinoma lung small cell carcinoma bladder urothelial carcinoma ovary epithelial cancer ureter transitional cell carcinoma breast cancer gastroesophageal junction adenocarcinoma hypopharynx cancer renal pelvis transitional cell carcinoma laryngeal squamous cell carcinoma peritoneum cancer lung non-small cell carcinoma cervical adenosquamous carcinoma gastric adenocarcinoma pancreatic adenocarcinoma fallopian tube cancer urethra transitional cell carcinoma oropharynx cancer urinary bladder cancer transitional cell carcinoma triple-receptor negative breast cancer Her2-receptor negative breast cancer oral squamous cell carcinoma cervical adenocarcinoma endometrial carcinoma
Therapies	SKB264
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| CAN

No variant requirements are available.